Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G

Rhea-AI Filing Summary

Oramed Pharmaceuticals Inc. reports a Schedule 13G disclosure that Aquamarine Financial (Cayman) Ltd beneficially owns 2,047,652 shares of common stock. The filing shows this represents 5.06% of the class with sole voting and dispositive power over those shares. The form is signed by a director on 05/13/2026.

Insights

Institutional Ownership Analyst

Large passive holder reports a 5.06% stake in Oramed.

The Schedule 13G filing lists Aquamarine Financial (Cayman) Ltd as beneficial owner of 2,047,652 shares with sole voting and dispositive power. The filing type and signature indicate a passive/beneficial ownership disclosure rather than an active trading announcement.

Ownership at 5.06% crosses common reporting thresholds; subsequent filings could show changes. Review future disclosures for any conversion to an active Schedule 13D or amendments that would signal an activist intent.

Key Figures

Shares beneficially owned: 2,047,652 shares Percent of class: 5.06% Sole voting power: 2,047,652 shares +3 more

6 metrics

Shares beneficially owned 2,047,652 shares Amount beneficially owned per Schedule 13G

Percent of class 5.06% Percent of common stock represented by the reported shares

Sole voting power 2,047,652 shares Number of shares with sole power to vote as stated in Ownership section

Sole dispositive power 2,047,652 shares Number of shares with sole power to dispose as stated in Ownership section

Signature date 05/13/2026 Date on signature block of the filing

Document header date 01/14/2026 Date appearing in the document header

Key Terms

Schedule 13G, Beneficially owned, Sole Voting Power, Sole Dispositive Power

4 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: ORAMED PHARMACEUTICALS INC."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned regulatory

"Item 4. Ownership (a) Amount beneficially owned: 2,047,652"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power regulatory

"5 | Sole Voting Power 2,047,652.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"7 | Sole Dispositive Power 2,047,652.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ORAMED PHARMACEUTICALS INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

68403P203

(CUSIP Number)

01/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 68403P203

1

Names of Reporting Persons

Aquamarine Financial (Cayman) Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,047,652.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,047,652.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,047,652.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.06 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ORAMED PHARMACEUTICALS INC.
(b)	Address of issuer's principal executive offices: 1185 Avenue of the Americas, 3rd Fl, New York, New York,10036
Item 2.
(a)	Name of person filing: Aquamarine Financial (Cayman) Ltd
(b)	Address or principal business office or, if none, residence: 23 Lime Tree Bay Avenue, Grand Cayman, Cayman Islands KY1-1002
(c)	Citizenship: Cayman Islands
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 68403P203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,047,652
(b)	Percent of class: 5.06 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,047,652
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,047,652
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aquamarine Financial (Cayman) Ltd

Signature:	/s/ David Mungall
Name/Title:	Director
Date:	05/13/2026

FAQ

What stake does Aquamarine Financial hold in ORMP?

Aquamarine Financial holds 2,047,652 shares, representing 5.06% of Oramed's common stock. The Schedule 13G states the filer has sole voting and dispositive power over those shares and lists the filer’s Cayman Islands address.

What does the Schedule 13G filed for ORMP indicate?

The Schedule 13G indicates a beneficial ownership disclosure for a passive investor holding over 5.00% of the class. It reports share counts, voting/dispositive power, and is signed by a director on 05/13/2026.

Does this filing show Aquamarine intends to control Oramed (ORMP)?

No intent to control is stated; the filing is a Schedule 13G disclosure of beneficial ownership at 5.06%. The form type typically signals passive reporting rather than an explicit control or activist intent.

Who has voting and dispositive power over the reported shares?

Aquamarine Financial (Cayman) Ltd is reported to have sole voting power of 2,047,652 shares and sole dispositive power of the same amount, per the filing's Ownership section.

When was the Schedule 13G signed for ORMP?

The signature block shows the filing was signed by a director on 05/13/2026. The top of the excerpt also references the date 01/14/2026 in the header area of the document.